| [1] |
中华人民共和国国家卫生和计划生育委员会医政医管局, 中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2017年版)[J]. 中国实用外科杂志, 2018, 38(10): 1089-1103. 3-23. DOI: 10.19538/j.cjps.issn1005-2208.2018.10.01.
|
| [2] |
中国医师协会结直肠肿瘤专委会腹膜肿瘤专业委员会. 结直肠癌腹膜转移诊治中国专家意见(2017)[J]. 中华结直肠疾病电子杂志, 2017,6(5):360-366. DOI: 10.3877/cma.j.issn.2095-3224.2017.05.002.
|
| [3] |
Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer[J]. Lancet, 2010,375(9719):1030-1047. DOI: 10.1016/S0140-6736(10)60353-4.
doi: 10.1016/S0140-6736(10)60353-4
pmid: 20304247
|
| [4] |
Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase Ⅲ trials N9741 and N9841[J]. J Clin Oncol, 2012,30(3):263-267. DOI: 10.1200/JCO.2011.37.1039.
doi: 10.1200/JCO.2011.37.1039
|
| [5] |
Yonemura Y, Bandou E, Kawamura T, et al. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer[J]. Eur J Surg Oncol, 2006,32(6):602-606. DOI: 10.1016/j.ejso.2006.03.003.
pmid: 16617004
|
| [6] |
Koppe MJ, Boerman OC, Oyen WJ, et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies[J]. Ann Surg, 2006,243(2):212-222. DOI: 10.1097/01.sla.0000197702.46394.16.
doi: 10.1097/01.sla.0000197702.46394.16
pmid: 16432354
|
| [7] |
何振华, 张森, 宋现青, 等. 结直肠癌腹膜种植转移的相关因素分析[J] 中国肿瘤临床, 2013,40(2):107-110. DOI: 10.3969/j.issn.1000-8179.2013.02.012.
doi: doi:10.3969/j.issn. 1000-8179.2013.02.012
|
| [8] |
Lemmens VE, Klaver YL, Verwaal VJ, et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study[J]. Int J Cancer, 2011,128(11):2717-2725. DOI: 10.1002/ijc.25596.
doi: 10.1002/ijc.25596
pmid: 20715167
|
| [9] |
Segelman J, Granath F, Holm T. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer[J]. Br J Surg, 2012,99(5):699-705. DOI: 10.1002/bjs.8679.
pmid: 22287157
|
| [10] |
Elias D, Glehen O, Pocard M, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix[J]. Ann Surg, 2010,251(5):896-901. DOI: 10.1097/SLA.0b013e3181d9765d.
doi: 10.1097/SLA.0b013e3181d9765d
pmid: 20395843
|
| [11] |
Turaga K, Levine E, Barone R, et al. Consensus guidelines from the American society of peritoneal surface malignancies on standar-dizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States[J]. Ann Surg Oncol, 2014,21(5):1501-1505. DOI: 10.1245/s10434-013-3061-z.
doi: 10.1245/s10434-013-3061-z
|
| [12] |
Votanopoulos KI, Swett K, Blackham AU, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from rectal cancer[J]. Ann Surg Oncol, 2013,20(4):1088-1092. DOI: 10.1245/s10434-012-2787-3.
doi: 10.1245/s10434-012-2787-3
|
| [13] |
Sato H, Kotake K, Sugihara K, et al. Clinicopathological factors associated with recurrence and prognosis after R0 resection for stage Ⅳ colorectal cancer with peritoneal metastasis[J]. Dig Surg, 2016,33(5):382-391. DOI: 10.1159/000444097.
doi: 10.1159/000444097
pmid: 27119565
|
| [14] |
Glehen O, Cotte E, Schreiber V, et al. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin[J]. Br J Surg, 2004,91(6):747-754. DOI: 10.1002/bjs.4473.
pmid: 15164446
|
| [15] |
锁涛, 童汉兴, 万柳华, 等. 中国大陆腹腔热灌注化疗治疗胃肠癌腹膜转移癌的现状[J]. 中国肿瘤临床, 2012,39(22):1754-1756. DOI: 10.3969/j.issn.1000-8179.2012.22.016.
doi: doi:10.3969/j.issn.1000-8179.2012.22.016
|
| [16] |
宋文灿, 潘明, 徐金发, 等. 雷替曲塞联合奥沙利铂在结直肠癌一线治疗失败后的临床应用[J]. 安徽医学, 2014,35(5):641-644. DOI: 10.3969/j.issn.1000-0399.2014.05.029.
|
| [17] |
Oliphant R, Horgan PG, Morrison DS, et al. Validation of a modified clinical risk score to predict cancer-specific survival for stage Ⅱ colon cancer[J]. Cancer Med, 2015,4(1):84-89. DOI: 10.1002/cam4.352.
doi: 10.1002/cam4.352
pmid: 25487740
|
| [18] |
Tanner EJ, Black DR, Zivanovic O, et al. Patterns of first recu-rrence following adjuvant intraperitoneal chemotherapy for stage ⅢC ovarian cancer[J]. Gynecol Oncol, 2012,124(1):59-62. DOI: 10.1016/j.ygyno.2011.09.011.
pmid: 21982046
|
| [19] |
张微, 邹玺, 胡玥, 等. 雷替曲塞联合伊立替康与FOLFIRI方案二线治疗晚期结直肠癌的近期疗效[J]. 现代肿瘤医学, 2015,23(11):1550-1552. DOI: 10.3969/j.issn.1672-4992.2015.11.22.
|
| [20] |
Li L, Huang XE. Thalidomide combined with chemotherapy in treating patients with advanced lung cancer[J]. Asian Pac J Cancer Prev, 2016,17(5):2583-2585.
pmid: 27268634
|
| [21] |
赵海波, 李胜范. 大肠癌根治术后静脉化疗联合腹腔化疗疗效分析[J]. 当代医学, 2009,15(1):80-81. DOI: 10.3969/j.issn.1009-4393.2009.01.059.
|
| [22] |
Zhao P, Ding Z, Tang L, et al. Preliminary investigation of intra-peritoneal raltitrexed in patients with gastric cancer[J]. World J Surg Oncol, 2014,12:403. DOI: 10.1186/1477-7819-12-403.
doi: 10.1186/1477-7819-12-403
pmid: 25547003
|
| [23] |
胡军, 段浩清, 罗俊峰, 等. 雷替曲塞术中腹腔灌注化疗对结直肠癌的安全性和近期疗效研究[J]. 中国医学创新, 2018,15(31):17-20. DOI: 10.3969/j.issn.1674-4985.2018.31.005.
|
